Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61P - Specific therapeutic activity of chemical compounds or medicinal preparations › A61P 25 - Drugs for disorders of the nervous system
Patents for A61P 25 - Drugs for disorders of the nervous system (183,225)
03/2005
03/17/2005US20050059084 Using presence of preferential helical structure in protein to diagnose/prognose prion and nervous system disorders; treatment and prevention alzheimer's and spongiform encephalopathy
03/17/2005US20050059081 Dipeptidyl peptidase IV (DPPIV); homology with family of prolyl oligopeptidases; drug screening for enzyme inhibitors for DPPIV which could treat reproductive, inflammatory and metabolic disorders; antibodies for therapeutic or diagnostic use; host cells
03/17/2005US20050059040 Guidance receptor protein for use as tool in identifying modlator for use in treatment and preventio of nervous system disorders
03/17/2005US20050059006 Using presence of polymorphism in ciliary neurotrophic factor (CNTF) gene sequences as diagnostic indicator for lloperidone treatment of psychotic disorders
03/17/2005US20050058999 Gene involved in apoptosis regulation
03/17/2005US20050058733 Health food products
03/17/2005US20050058732 Herbal pharmaceutical composition for treating siriasis and its process
03/17/2005US20050058706 Delayed release pharmaceutical composition containing 3-(3-dimethylamino-1-ethyl-2-methyl-propyl)phenol
03/17/2005US20050058666 Method for treating pain by peripheral administration of a neuroptoxin
03/17/2005US20050058643 Binding to major histocompatibility complex; immunosuppression; therapy, prevention multiple sclerosis
03/17/2005US20050058639 Antibodies directed to monocyte chemo-attractant protein-1 (MCP-1) and uses thereof
03/17/2005US20050058623 Use of gp130 activators in diabetic neuropathy
03/17/2005DE10338403A1 Pulverformulierung, enthaltend den CGRP-Antagonisten Powder formulation comprising the CGRP-antagonists 1-[N2-[3,5-Dibrom-N-[[4-(3,4-dihydro-2(1H)-oxochinazolin-3-yl]-1-piperidinyl]carbonyl]-D-tyrosyl]-L-lysyl]-4-(4-pyrindinyl)-piperazin, Verfahren zu dessen Herstellung sowie dessen Verwendung als Inhalativum Process for its preparation and its use as Inhalativum
03/17/2005DE10337074A1 Verwendung der Inhibitoren von Enzymen mit Aktivitäten der Aminopeptidase N und/oder der Dipeptidylpeptidase IV und pharmazeutischen Zubereitungen daraus zur Therapie und Prävention von chronischen neurodegenerativen Erkrankungen Use of inhibitors of enzymes with activities of aminopeptidase N and / or of dipeptidyl peptidase IV and pharmaceutical preparations thereof for the treatment and prevention of chronic neurodegenerative diseases
03/17/2005DE102004040243A1 Transport system for overcoming the blood-brain barrier, useful for the treatment and diagnosis of brain-specific diseases, comprises chitin, chitosan, chitosan oligosaccharides or glucosamine
03/17/2005CA2542339A1 Combination of serotonin reuptake inhibitors and norepinephrine reuptake inhibitors
03/17/2005CA2538135A1 1-benzoyl-piperazine derivatives as glycine uptake inhibitors for the treatment of psychoses
03/17/2005CA2537883A1 Substituted bicyclic quinazolin-4-ylamine derivatives
03/17/2005CA2537829A1 Heteroaryl fused pyridines, pyrazines and pyrimidines as crf1 receptor ligands
03/17/2005CA2537802A1 Composition containing nanoparticles containing water-soluble basic drug encapsulated therein
03/17/2005CA2537757A1 The combination of a serotonin reuptake inhibitor and amoxapine
03/17/2005CA2537747A1 The combination of a serotonin reuptake inhibitor and loxapine
03/17/2005CA2537292A1 1- (2-amino-benzol) -piperazine derivatives as glycine uptake inhibitors for the treatment of psychoses
03/16/2005EP1514930A1 Novel screening method
03/16/2005EP1514925A1 Method of screening compound affecting amyloid beta production
03/16/2005EP1514877A1 Complex of organic medicines and beta-cyclodextrin derivatives and its preparing process
03/16/2005EP1514869A1 Indole, indazole, and benzazole derivative
03/16/2005EP1514559A1 Arylpiperazines having activity at the serotonin 1a receptor
03/16/2005EP1514558A1 Use of MARKK or MARKK antagonists for the treatment of pathologies characterised by increased or reduced phosphorylation of MARK or tau protein
03/16/2005EP1514556A1 Botulinum toxin pharmaceutical compositions
03/16/2005EP1514555A1 Polyherbal formulation for hepatic and splenic disorders
03/16/2005EP1514542A1 Medicinal compositions improving brain function and method for improving brain function
03/16/2005EP1513955A2 Diagnostic and therapeutic use of cyp11a1 for neurodegenerative diseases
03/16/2005EP1513941A2 Preparation of microbial oil containing polyunsaturated fatty acids
03/16/2005EP1513924A1 Attenuated listeria spp. and methods for using the same
03/16/2005EP1513922A1 Pasteurisation process for microbial cells and microbial oil
03/16/2005EP1513864A2 Therapeutic polypeptides, nucleic acids encoding same, and methods of use
03/16/2005EP1513858A2 Process for the preparation of heterocyclyl substituted adenosine derivatives
03/16/2005EP1513846A1 Process of preparation of olanzapine form i
03/16/2005EP1513842A1 Substituted hexahydropyrrolo (1,2-a)pyrazines, octahydropyrido(1,2-a)pyrazines and decahydropyrazino(1,2-a)azepines
03/16/2005EP1513839A1 3-substituted quinuclidines and their use
03/16/2005EP1513837A1 Thiazole derivatives as phosphodiesterase iv inhibitors
03/16/2005EP1513836A1 Piperazinylacylpiperidine derivatives, their preparation and therapeutic use thereof
03/16/2005EP1513835A1 Piperazinylacylpiperidine derivatives, their preparation and therapeutic use thereof
03/16/2005EP1513834A1 Substituted thiophenes, method for the production thereof, their use as a medicament or diagnostic reagent, and a medicament containing the same
03/16/2005EP1513831A1 Novel compounds, their use and preparation
03/16/2005EP1513830A1 Bisindolyl-maleimid derivatives as kinase inhibitors
03/16/2005EP1513828A1 New compounds useful for the treatment of obesity, type ii diabetes and cns disorders
03/16/2005EP1513827A1 1,3,5-triazine derivatives as ligands for human adenosine-a3 receptors
03/16/2005EP1513821A1 Protein kinase inhibitors
03/16/2005EP1513814A1 Novel piperidine compound
03/16/2005EP1513810A1 4-(aryl or heteroaryl) -2-butylamine derivatives and their use as glucocorticoid ligans
03/16/2005EP1513809A1 1-sulfonyl-4-aminoalkoxy indole derivatives as 5-ht6-receptor modulators for the treatment of cns-disorders
03/16/2005EP1513808A2 Fluorinated cyclic amides as dipeptidyl peptidase iv inhibitors
03/16/2005EP1513806A1 New salts
03/16/2005EP1513797A1 Agents and methods for the treatment of disorders associated with oxidative stress
03/16/2005EP1513796A2 Phenyloxyalkanoic acid derivatives as hppar activators
03/16/2005EP1513795A2 Propionic acid derivatives and their use as hppars activators
03/16/2005EP1513589A1 1,5-disubstituted pyrrolid-2-one derivatives for use as ep4 receptor agonists in the treatment of eye diseases such as glaucoma
03/16/2005EP1513588A2 Use of new etonogestrel esters
03/16/2005EP1513560A2 Method of magnetically manipulating a cell with magnetisable particles
03/16/2005EP1513543A2 Fas peptide mimetics and uses thereof
03/16/2005EP1513536A1 Use of compounds that stimulate cgmp
03/16/2005EP1513535A2 Controlled release formulation of lamotrigine
03/16/2005EP1513533A2 Pharmaceutical active substance combination and the use thereof
03/16/2005EP1513531A1 Basic non-peptide bradykinin antagonists and pharmaceutical compositions therefrom
03/16/2005EP1513529A1 Triple monoamine reuptake inhibitors for the treatment of chronic pain
03/16/2005EP1513528A1 Pharmaceutical composition containing stabilised amorphous form of donepezil hydrochloride
03/16/2005EP1513526A1 Phenylalkanoic acid and phenyloxyalkanoic acid derivatives as hppar activators
03/16/2005EP1513524A2 Ether substituted imidazopyridines
03/16/2005EP1513520A2 Substituted pyrrolines as kinase inhibitors
03/16/2005EP1513518A1 Use of nefopam for the treatment of nausea or emesis
03/16/2005EP1513517A1 Formulation of nefopam and its use in the treatment of pain
03/16/2005EP1513516A1 SUBSTITUTED 3-AMINO-THIENO(2,3-b) PYRIDINE-2-CARBOXYLIC ACID AMIDE COMPOUNDS ANDPROCESSES FOR PREPARING AND THEIR USES
03/16/2005EP1513511A1 (2s)-2-amino-4- [2-(ethanimidoylamino)ethyl]thio butanoic acid, a nitric oxide synthase inhibitor, in stabilized pharmaceutical dosage forms
03/16/2005EP1513510A1 The use of milnacipran for the treatment of tension-type headache
03/16/2005EP1513507A1 Transdermal analgesic systems with reduced abuse potential
03/16/2005EP1513504A1 Sustained release oral dosage forms of gabapentin
03/16/2005EP1513503A1 Extended release formulation of divalproex sodium
03/16/2005EP1513499A1 Ibuprofen suspension
03/16/2005EP1513497A2 Dosage forms and compositions for osmotic delivery of variable dosages of oxycodone
03/16/2005EP1513495A1 Modified release pharmaceutical formulation
03/16/2005EP1513494A2 Film-shaped mucoadhesive administration form for administering cannabis active ingredients
03/16/2005EP1513493A2 Analgesics
03/16/2005EP1513419A2 Method and composition for treating or preventing catabolism or stimulating anabolism in a mammal undergoing metabolic stress
03/16/2005EP1513403A1 Cardiac glycosides to treat cystic fibrosis and other il-8 dependent disorders
03/16/2005EP1453510A4 Neurotransmitter balance chemotherapy
03/16/2005EP1425283B1 Novel 4-aminofuropyrimidines and the use thereof
03/16/2005EP1392699B1 6h-oxazolo 4,5-e]indole derivatives as nicotinic acetylcholine receptor ligands and/or serotonergic ligands
03/16/2005EP1250358B1 Therapeutic peptides
03/16/2005EP1233959B1 Heterocyclo-alkylsulfonyl pyrazole derivatives as anti-inflammatory/analgesic agents
03/16/2005EP1189640B1 Complex of eletriptan and sulphobutylether-cyclodextrin and its use for the treatment of migraine
03/16/2005EP1135134B1 Use of neurotrophic factor stimulators for the treatment of ophthalmic neurodegenerative diseases
03/16/2005EP1135125B1 Controlled-release dosage forms comprising zolpidem or a salt thereof
03/16/2005EP1000065B1 Preparation of oxymorphone, oxycodone and derivatives
03/16/2005EP0952772B1 Methods of use of mononuclear phagocytes to promote axonal regeneration
03/16/2005EP0874625B1 Indane derivatives for antipsychotic compositions
03/16/2005CN1596263A Aryl fused azapolycyclic compounds
03/16/2005CN1596258A Adenosine A2a receptor antagonists
03/16/2005CN1596257A Novel crystalline compound
1 ... 991 992 993 994 995 996 997 998 999 1000 1001 1002 1003 1004 1005 1006 1007 1008 1009 1010 1011 ... 1833